From: Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor
Patients
Clustering (%)
Baseline
7 days post-therapy
28 days post-therapy
1
67.8
54.3
2
62.1
77.1
73.9
3
67.4
66.7
72.7
4
51.5
49.0
78.2
5
61.6
–*
75.8
6
44.2
83.8
80.3